Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

Morgan Stanley analyst Chris Quintero raised the firm’s price target on Vertex (VERX) to $62 from $50 and keeps an Overweight rating on the shares. The firm has greater conviction in Vertex being a ...

Vertex (VERX – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Chris Quintero from ...

Vertex, Inc. VERX reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance on ...

Across the recent three months, 6 analysts have shared their insights on Vertex VERX, expressing a variety of opinions spanning from bullish to bearish. The table below offers a condensed view of ...

Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and welcome to the Vertex Inc. Third Quarter 2024 ...

The headline numbers for Vertex (VERX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ETCompany ParticipantsJoe Crivelli - Vice President, ...

Grant Thornton, one of America’s largest brands of professionals providing end-to-end audit, assurance, tax and advisory services, has been named the Vertex System Integrator Partner of the Year for ...

Palantir, Microchip Technology, and Arm Holdings are among the technology firms reporting this week, while pharmaceutical ...

Amy McCarthy is a reporter at Eater.com, focusing on pop culture, policy and labor, and only the weirdest online trends. Sure, it’s only October, but if you want a really great advent calendar ...